Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2025-04-09 00:00:00 ET · period of report 2025-04-07 · accession 0000919574-25-002362 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2025-04-09 | 2025-04-07 | BLFS | Casdin Partners GP, LLC | 10% | J - Other | — | +28.0K | 8.74M | +0.3% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, par value $.001 per share | 2025-04-07 | J | A | 27,994 | — | 8,735,159 | I See footnote | — | — | (F1) Received in exchange for shares of common stock of PanThera CryoSolutions, Inc. ("PanThera") pursuant to the acquisition of PanThera by Biolife Solutions Inc (the "Company"). Per the terms of the acquisition, the Company purchased 90% of PanTHERA common shares it did not own for $9.3 million in cash and 241,355 shares of the Company's Common Stock, par value $.001 per share. The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. |